![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEibsU-Mvh6TfHGUCrTcmDNV5rcAv7XKXrhW1ZTrahW0HFBr-eIKouTdq_Xsb4P_ALggFlWJOKXK6IGPYp6OaRcxRgjvNs7luhK2HLhAcj1xmIGY2ZoWN-QPsA34THz3pIRZsAtVNjrEO-0/s1600/AYLA-i.jpg)
Underwriters' over-allotment will be up to an additional 500K shares.
The Rehovet, Israel-based biopharmaceutical outfit develops treatments for rare and aggressive cancers by leveraging its bioinformatics platform and next-gen sequencing.
https://www.ayalapharma.com/
No comments:
Post a Comment